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Introduction
Transfer and expression of genes mediating resistance to cytotoxic agents is a promising approach to circumvent the dose-limiting myelotoxicity of cancer chemotherapy as well as to establish an in vivo selectable phenotype in gene-modified hematopoietic cells. 1, 2 Pioneering clinical trials [3] [4] [5] and our own preclinical work [6] [7] [8] indicated that improvements in vector design, transduction conditions, and cancer drug regimens would be necessary to achieve efficacy. Substantial progress may be obtained by developing vectors that allow selective enrichment of gene-modified and chemoprotected cells before reinfusion. Such vectors may allow: (1) purification of transduced and vector-expressing graft cells without exposure to cytotoxic agents; and (2) expansion of chemoprotected cells to significant numbers ex vivo. Then, engraftment may occur with sufficient chemoprotected progenitor cells, hopefully providing clinically valuable protection starting with the first phase of intensified chemotherapy. Moreover, the high sensitivity of improved cell-surface markers 9 may alleviate the monitoring of transduced cells in vivo. Thus, a detailed analysis of biological characteristics of transduced cells and of the putative differentiation-dependent vector expression would be possible in clinical trials.
All chemoprotecting genes proposed for clinical application are of human origin and, for several reasons, do not allow enrichment of transduced cells without exposure to cytotoxic drugs. Many of these genes encode either cytoplasmic enzymes, eg aldehyde dehydrogenase 10 and mutant dehydrofolate reductase, 11 or nucleusassociated activities, eg lung resistance protein 12 and O 6 -alkylguanine-DNA-alkyltransferase. 13 The only chemoprotective proteins presenting cell-surface located domains are the multidrug resistance protein, MRP, 14 and the P-glycoprotein (Pgp) encoded by the multidrugresistance 1 gene (MDR1). 1 However, high endogenous background in primitive hematopoietic cells 15, 16 and low sensitivity of available antibodies preclude clear separation of transduced cells from untransduced controls by antibody-labeling, even when potent retroviral vectors are used (Eckert, Hildinger and Baum, unpublished results) .
On the other hand, a number of highly sensitive cellsurface markers have been identified which may be neither immunogenic nor toxic when expressed in a heterologous background. 9 These allow enrichment of transduced cells by preparative flow cytometry, 17 or using immunoaffinity columns which can be applied in clinical settings. 18, 19 One promising marker is the cytoplasmically truncated, signalling-domain deficient version of the human low-affinity nerve growth factor receptor (DLNGFR). 18, 19 In this study, we present vectors that combine the expression of MDR1 and of DLNGFR. These vectors are based on the FMEV backbone which contains cis-active elements selected for high levels of gene expression in transduced hematopoietic progenitors. 6, 20 FMEV:MDR1 vectors mediate high-dose multidrug resistance in primary and early hematopoietic cells 7 even when coexpressing a second gene. 8 Moreover, the transcriptional strength of FMEV vectors in hematopoietic cells significantly improves the detectability of marker gene expression. 20 We show that (1) linking both genes with alternative splicing signals or an internal ribosomal entry site (IRES) leads to a strong correlation of their expression levels in single cells; (2) the combination of cell-surface marking with myeloprotection allows the detection of transduced and chemoresistant cells with high sensitivity; and (3) vector-expressing, multidrug resistant cells can be enriched in vitro, without exposure to cytotoxic agents.
Results

Cloning of vectors
To develop vectors that coexpress DLNGFR besides MDR1, the cDNAs were tailored by PCR to remove residual untranslated sequences and to create Kozak-consensus sequences at the start codons for optimal initiation of translation. The MDR1 cDNA was placed in the LTRcontrolled 5′ position to achieve optimal expression levels required for stringent drug resistance. 8 The DLNGFR cDNA was placed 3′ of the MDR1 transcription unit using three different strategies ( Figure 1 ): (1) an alternative subgenomic message for DLNGFR was generated by introducing a fragment of the pol pseudogene of SFFVp 8, 21 which contains the retroviral pyrimidine tract, the branch site and the splice acceptor (vector SF1mSd) for the 3′ positioned gene; (2) the IRES of the encephalomyocarditis virus (EMCV) 22 was cloned in frame with the DLNGFR cDNA to allow cap-independent translation (vector SF1mEd); (3) an internal promoter of the chicken b-actin gene 23 was used to drive expression of DLNGFR (vector SF1mbd). This promoter is about five times less active than the LTR of FMEV in myeloid progenitor cells (Baum, unpublished data) .
Two monocistronic control vectors were used: SF1m expresses the tailored MDR1 gene from an FMEV backbone; MO3d expresses DLNGFR under control of cis-active elements derived from the Moloney murine leukemia virus (MoMLV). 20 Two-color flow cytometry to evaluate connection strategies in single cells: a good correlation of coexpression is found with splice and IRES, but not with the internal promoter The different vector plasmids were transfected into safety-modified packaging cells GP&Env Am12. Transfected cells producing replication-defective amphotropic vectors were used for retroviral transduction of human cells K562, DAUDI or CCRF-CEM. Transductions were performed at a multiplicity of infection (MOI) ,0.1 to assure single copy integrations. Mass cultures of transduced cells were established by selecting with lethal doses of colchicine (20 ng/ml), an antimitotic agent which is recognized by the MDR1-encoded drug efflux pump, Pgp. Vector function was evaluated using twocolor flow cytometry, simultaneously monitoring expression levels of Pgp and DLNGFR. Double-staining of transduced and MDR1-selected cells with monoclonal antibodies UIC2 (directed against an extracytoplasmic epitope of Pgp) and a-DLNGFR revealed co-expression of both markers at the single cell level, but with striking differences related to the linking principle ( Figure 2 ).
Of note, staining of multidrug-resistant cells with UIC-2 resulted in a population shift, but was not sensitive enough to detect clearly enhanced expression of Pgp in all multidrug-resistant cells when compared with the untransduced control. This reflects a suboptimal sensitivity of this antibody (see also Figure 3a ). Taking into account that all cells analyzed had acquired dominant multidrug-resistance and that the UIC2-staining was not sensitive enough to show all cells overexpressing Pgp, the percentages of cells co-expressing DLNGFR were determined solely based on the fluorescence achieved with a-DLNGFR. This staining perfectly separated positive from negative cells, as documented by the appearance of two populations in Figure 2a -c.
Criteria for assessing the quality of the connecting module were high levels of expression of both proteins with a strong mutual correlation. Both splice and IRES, but not the internal promoter, provided a strong positive correlation of expression of DLNGFR with the intensity of Pgp-labeling. The splice vector, SF1mSd, produced the highest frequency of DLNGFR-positive cells (97%), followed by the vector with the IRES, SF1mEd (81%), and the vector with the internal promoter, SF1mbd (78%). Among the bicistronic vectors tested, SF1mSd mediated the highest expression levels of DLNGFR. Similar levels were achieved with SF1mbd, but SF1mEd was significantly less potent (Figure 2a-c) .
To demonstrate that the mutual correlations of protein expression observed were not due to staining artifacts or poor compensation in two-color flow cytometry, a control was included by superinfecting cells transduced with the monocistronic DLNGFR vector, MO3d with the monocistronic MDR1 vector, SF1m, and selecting cells for multidrug resistance as described above. In the resulting mass culture, DLNGFR expression was entirely independent of Pgp-intensity ( Figure 2d ). This result underlines the utility of two-color flow cytometry for evaluating connection strategies in bicistronic vectors.
With any bicistronic vector tested, DLNGFR levels achieved were reduced and more variable compared with cells transduced with a monocistronic FMEV vector expressing DLNGFR 20 or with a monocistronic vector expressing DLNGFR under control of the weaker MoMLV-LTR (vector MO3d Figure 2d ). Still, expression of DLNGFR from the bicistronic vectors was high enough to separate transduced cells from untransduced controls.
Impaired expression of multidrug resistance with the coexpression vectors Bicistronic MDR1 vectors mediate reduced expression of multidrug resistance compared to monocistronic MDR1-vectors. 8 This may compromise safety and utility in clinical trials. An overlay of the Pgp histograms indicated that the construct with the internal promoter (SF1mbd) may mediate suboptimal multidrug resistance (Figure 3a) . This was confirmed when investigating the potency of the vectors for inducing multidrug resistance in the presence of increasing doses of the antimitotic agent colchicine (Figure 3b) . Compared with cells transduced with the monocistronic MDR1 vector, those transduced with 
(a) Expression levels of MDR1-encoded Pgp detected with the PE-conjugated anti-Pgp antibody UIC-2. (b) Cloning efficiency in semi-solid media containing increasing does of colchicine.
SF1mEd or SF1mSd showed moderately impaired chemoprotection (less than two-fold reduction in cloning efficiency with doses of colchicine up to 20 ng/ml). The splice vector (SF1mSd) was slightly less potent than the IRES vector (SF1mEd). This can be explained by a partial loss of MDR1-encoding transcripts resulting from the activity of the retroviral splice sites.
As expected from the weaker antibody labeling (Figure 2a ), cells transduced with the internal promoter construct (SF1mbd) suffered from further reduced multidrug resistance. This indicated negative transcriptional interference between the LTR and the internal promoter, which is in line with the results obtained by two-color flow cytometry (see above and Figure 2 ).
High selectable titers of the splice vector, SF1mSd can be achieved using safety-modified packaging cells The data accumulated thus far revealed that the splice connection was a good choice for co-expression of MDR1 and DLNGFR. With respect to the three criteria described above (expression levels of DLNGFR, positive correlation in the expression of the cell-surface marker and of the myeloprotective gene, and strength of multidrug resistance), cells transduced with SF1mSd showed a reasonable performance. Therefore, all further studies were performed with SF1mSd. An uncloned mass culture of GP&EnvAm12 cells retrovirally transduced with SF1mSd produced the vector to titers of 5 × 10 4 infectious units, as determined by end-point dilution of cell-free supernatant on HT1080 human fibrosarcoma cells and subsequent selection of multidrug resistant clones with 20 ng colchicine per milliliter. For comparison, mass cultures producing SF1mEd had higher (25% increased), those producing SF1mbd lower titers (60% of SF1mSd). Some individual clones had higher titers than the mass cultures. Thus, we isolated a clone producing 5-6 × 10 5 MDR1-transducing units of SF1mSd per milliliter supernatant. This is good value for a splice-connected bicistronic MDR1 vector. 8 Titers of this clone remained stable during large-scale production. (Figure 4a, d ) and of DLNGFR (Figure 4b, e) at the cell membrane, with a spotted staining pattern. In some areas the stainings were overlapping, indicating that the epitopes were presented in close vicinity (Figure 4c, f) . Most likely, this represented coincidence of the localizations of both proteins (see Discussion).
Simultaneous presentation of MDR1 and
The splice vector, SF1mSd, is functional in myeloid and lymphoid cells To confirm that SF1mSd is functional in other human cell types besides K562, we transduced T-lymphoblastoma (CCRF-CEM) and Burkitt lymphoma cells (DAUDI), again using a low MOI. Transduced cells were selected with 20 ng colchicine per milliliter, and mass cultures subjected to two-color flow cytometry ( Figure 5 ). Similar to the results obtained with K562 cells (see above, Figure 2a ), multidrug-resistant cells also expressed DLNGFR. Depending on the cell type, interesting differences in the respective expression levels of Pgp and of DLNGFR were seen. CCRF-CEM cells had medium levels of Pgp, but showed strong expression of DLNGFR. DAUDI cells were equivalent to K562 in expressing Pgp, but had lower levels of DLNGFR. Contour blot analyses always revealed an almost linear rise in expression of DLNGFR with increasing levels of Pgp. Taken together (Figures 3-5 ), these data demonstrate proper function of the splice vector (SF1mSd) in a variety of cell types representing several lineages of human myeloid and lymphoid hematopoiesis, with some differentiation-dependent variability in gene expression. Regardless of the cellular background, SF1mSd allowed stringent and sensitive detection of vector-transduced, multidrug resistant cells based on DLNGFR.
Primary human hematopoietic cells transduced with SF1mSd acquire multidrug resistance and can be enriched in vitro based on simultaneous expression of DLNGFR Besides being useful as a label for vector-transduced cells, co-expression of DLNGFR is also of interest to enrich vector-transduced cells for subsequent genetic or functional analyses. To address the feasibility of this approach, we analyzed co-expression of Pgp and DLNGFR before drug selection of cells transduced with SF1mSd. Under these circumstances, a significant population of DLNGFR-positive cells was expected to fail to express Pgp; this can be explained by rearrangements of the MDR1 transcription unit which occur in more than half of the vectors as a a b c d e f Figure 2 .
Figure 4 Simultaneous expression of MDR1 and DLNGFR in K562 cells transduced with SF1mSd demonstrated by confocal laser microscopy. Cells were antibody-labeled as described in Materials and methods, fixed and analyzed by confocal laser microscopy. a-c, Confocal imaging sections; d-f, surface view. a,d, expression of MDR1-encoded Pgp at the cell-surface; the internal stains observed correspond to membrane-impacts; b,e, expression of DLNGFR at the cell-surface. c,f, overlay of stains: in most areas, stains are distinct; overlapping expression (yellow) is observed in areas with high epitope-density.
Figure 5 Correlation of DLNGFR expression in multidrug resistant human T (CCREF-CEM) and B cells (DAUDI) transduced with SF1mSd. CCRF-CEM show high levels of DLNGFR, but low levels of Pgp. As compared with K562 cells (Figure 2a), DAUDI cells show moderate expression of DLNGFR and equal expression of Pgp. Staining procedures, isotype controls and instrument settings of the flow cytometer were as in the experiments shown in
result of internal splicing of the MDR1 transcription unit in packaging cells. 8, 24 Actually, about 36% of transduced K562 cells labeled with DLNGFR expressed Pgp in the absence of selection (Figure 6a ), indicating transduction with the correct copy of the vector. Similar ratios were also observed with transduced, yet unselected DAUDI and CCRF-CEM cells (data not shown). Thus, more than half of transduced cells presumably contained a truncated copy of the vector.
Next, we were interested to analyze whether enrichment of transduced and multidrug-resistant primary human CD34
+ cells was possible on the basis of DLNGFR expression. Experiments were performed using a previously described supernatant protocol which allows efficient transduction of NOD/SCID-mice repopulating human stem cells. 25 Control cells were transduced with the monocistronic DLNGFR vector. Twenty-four hours after completing the transduction protocol, cells were subjected to flow cytometric cell sorting, thus separating DLNGFR-positive from DLNGFR-negative cells. Based on expression of DLNGFR, the transduction efficiencies ranged from 12 to 50% of unselected CD34 + cells, depending on the MOI. Reanalysis of sorted cells confirmed .90% purity of DLNGFR-positive cells.
With and without cell sorting, transduced CD34 + cells were subjected to methylcellulose colony assays in the presence of colchicine. The drug concentration chosen (12 ng/ml) represents 2-3× the IC 50 of untransduced cells and results in background-free selection of cells transduced with FMEV:MDR1 vectors. 7 Accordingly, the colony-forming ability of control cells (mock-transduced or transduced with the monocistronic DLNGFR vector) was efficiently suppressed. Also, as predicted from the results obtained in unselected K562, DAUDI and CEM cells, no MDR1-transduced cells were observed in sorted, DLNGFR-negative populations of cells previously exposed to SF1mSd (Figure 6b) .
In contrast, colony-forming cells exposed to SF1mSd and sorted for expression of DLNGFR were clearly enriched for vector-mediated multidrug resistance. Thus, vector-transduced primary human hematopoietic cells had acquired dominant multidrug-resistance and were enriched ex vivo without exposure to cytostatic agents (Figure 6b ). However, as in K562 cells (Figure 6a ) enrichment did not exceed 35-40% of DLNGFR-positive cells, which can be attributed to well-documented genetic instability of the MDR1 sequences in retroviral vectors. 8, 24 Thus, the performance of the bicistronic vector SF1mSd was highly consistent in hematopoietic cell lines and in primary human hematopoietic cells.
Discussion
We have developed a vector utilizing alternative splicing for combined and codominant expression of the chemoprotective gene, MDR1, and of the clinically applicable cell-surface marker, DLNGFR, in human hematopoietic progenitor cells. We have shown that the vector mediates high-dose multidrug resistance in primary hematopoietic cells and reliably co-expresses DLNGFR in transduced, multidrug-resistant cells of erythroid, myeloid and lymphoid lineages. Thus, the cell-surface marker DLNGFR tags multidrug-resistant cells with high sensitivity. We have also demonstrated that the cell-surface marker allows enrichment of chemoresistant cells ex vivo, without exposure to cytostatic agents. However, due to genetic instability of the MDR1 coding sequences, 8, 24 more than half of transduced, but unselected cells failed to acquire a functional chemoresistance gene.
These data suggest that bicistronic vectors that combine a chemotherapy resistance gene with a clinically applicable cell surface marker may represent a useful tool to improve the genetic stability and functional performance of the vector further (see below) and to analyze the feasibility and the biological consequences of the chemoprotection approach. The latter aspect includes studies that address: (1) the ability to select chemoresistant cells using immunoaffinity-based techniques; 18 (2) the ability to expand drug-resistant cells dominantly in animal models 26, 27 including those for xenotransplantation of genetically engineered human stem cells; 25, 28 and (3) unexpected functional consequences that may be associated with the overexpression of drug-resistance genes in early hematopoietic cells and/or their forced expansion. 29 In clinical applications of chemoprotection, the cell-surface marker is expected to improve the detectability of trans- duced cells in specimens from repopulated patients. As indicated here with primary human hematopoietic cells, preparative cell sorting and functional analyses of vectorexpressing subpopulations should be possible with clinical material. Thus, combining myeloprotection with cellsurface marking may also create a valuable paradigm for non-oncologic gene therapy, eg cotransfer of drug-resistance genes with non-selectable genes for correction of inborn genetic disorders.
30
The splice-vector described here co-expresses MDR1 and a clinically relevant cell surface marker to dominant levels in primary human hematopoietic cells, regardless of the cellular background examined (human hematopoietic and lymphoid cell lines as well as primary hematopoietic cells). Interestingly, our confocal laser microscopy data revealed evidence for a partial colocalization of both proteins. For several independent reasons, this colocalization of the epitopes cannot be explained by a complex fusion protein: (1) overlapping stainings were restricted to patches with high fluorescence intensities; (2) a readthrough by skipping of stop codons or frameshifting was considered an extremely rare event, since multiple stop codons are present in the fragment of the pol pseudogene inserted upstream of the DLNGFR transcription unit (five, 11 or 16 stop codons in the three different reading frames, with a cluster of five stop codons found downstream of the retroviral splice acceptor preceding the start codon of DLNGFR in its reading frame); and (3) by sequence analysis and functional studies (data not shown) no evidence was obtained for a cryptic splice acceptor in DLNGFR which could interact with the cryptic splice donor in MDR1. Moreover, fusions resulting from internal splicing would not be expected to stain with UIC-2, because earlier data revealed that the epitope recognized by UIC-2 must be located downstream of the cryptic splice donor in MDR1. 8 At the single cell level, a stringent positive correlation of the expression of both proteins was observed when the transcription units were connected by alternative splicing or an IRES. An interesting methodical aspect of our study is the utility of two-color flow cytometry for the comparative analysis of different co-expression strategies. The suboptimal expression of DLNGFR under control of the IRES of EMCV may have resulted from incompatibilities in the secondary structure of the RNA, or from a reduced activity of this particular IRES in hematopoietic cells. Differentiation-dependent activity of an IRES is well established in other cell types. 31 Further improved expression of DLNGFR may be achieved by selecting another IRES, or by modifications in the splice signals. Compared with these strategies, any internal promoter is expected to be a poor choice. Problems resulting from transcriptional interference between the LTR and the internal promoter 32 were demonstrated in this study using two-color flow cytometry and drug resistance assays.
Vector function will also be improved if the endogenous instability of the MDR1 transcription unit were overcome. The incomplete penetrance of multidrug resistance in DLNGFR-selected CD34 + cells can be explained by the finding that more than half of transduced cells contain infunctional MDR1 transcription units, resulting from internal genetic alterations of the vector before integration. 8, 24 These events occur both in monocistronic 24 and bicistronic vectors, 8 and the frequency is largely independent of the 3′ located sequences, including those used for co-expression of a second gene. 8 Introducing silent mutations that prevent internal splicing 24 and additional mechanisms of instability 8 will render the vectors more stable and further raise expression levels of both encoded proteins. In this context, it is interesting to note that flow cytometric sorting of cells positive for the cell-surface marker, but negative for the MDR1-encoded epitope, can be used for rapid genetic diagnosis of breakpoints in the MDR1 cDNA. Thus, combining cell-surface markers with myeloprotective genes also generates a powerful approach for one of the basic steps toward successful gene therapy: the 'therapy' (fine tuning) of the vector.
Materials and methods
Vector construction
The FMEV-based retroviral vector plasmids pSF-MDR containing the MDR1 and pSF1d with the DLNGFR cDNA have been described. [6] [7] [8] In the co-expression vectors described in this study, all cDNAs were tailored by proofreading PCR to remove untranslated regions and Kozak consensus sequences were introduced at the start codons. For constructing the splice vector pSF1mSd, pSF1d was opened with NotI upstream of the DLNGFR cDNA and the 3.9 kb MDR1 coding sequences tailored with restriction sites NotI-SalI were jointly inserted with the retroviral splice acceptor and flanking retroviral sequences excised from pSF5+3 6 as a 600 bp fragment flanked with SalI and NotI restriction sites. A similar strategy yielded the IRES vector pSF1mEd and the internal promoter vector pSF1mbd using the 500 bp EMCV-IRES and the 300 bp chicken b-actin promotor, respectively, instead of the splice acceptor fragment. The IRES was tailored with XhoI and NotI by PCR; the internal promoter was excised from pSF1MbL 8 with restriction enzymes SalI and NotI.
PCR PCR was performed using recombinant Pfu Polymerase (Stratagene, Heidelberg, Germany) according to manufacturer's instructions. Amplification of the MDR1 cDNA was performed at 95°C 30 s, 50°C 30 s, 72°C 600 s (30 cycles) with SF-MDR as template, forward primer 5′-GCG-GCC-GCC-ATG-GAT-CTT-GAA-GGG-GAC-CGC-3′ and reverse primer 5′-TAC-CGT-CGA-CGT-ATC-GAT-AAG-3′. Amplification of the encephalomyocarditis IRES was performed at 95°C 30 s, 55°C 30 s, 72°C 60 s (30 cycles) with pBS-ECAT as template, forward primer 5′-CCG-GCT-CGA-GGT-TAC-TGG-CCG-AAG-CCG-CTT-GG-3′ and reverse primer 5′-ATA-GTT-TAG-CGG-CCG-CAT-TAT-CAT-CGT-GTT-TTT-CAA-AGG-3′. Sequencing of subcloned PCR products confirmed correct amplification.
Cell culture Retroviral packaging cells GP&env86 (ecotropic) and GP&envAm12 (amphotropic) were used as previously described. 8 Briefly, 10 mg of retroviral vector plasmid DNA were electroporated in GP&env86 cells; the supernatant was used to transduce GP&envAm12 cells. Selection was performed with colchicine (Sigma-Aldrich, Deisenhofen, Germany) at 40 ng/ml for all constructs. Surviving producers were pooled.
For establishment of a high-titer SF1mSd producer cell clone, 20 mg of retroviral vector plasmid DNA were electroporated into GP&envAm12 cells together with 1 mg of a plasmid expressing neomycinphosphotransferase II (neoR) under the control of the chicken b-actin promotor. Mass cultures were obtained upon selection with G418 at 400 mg/ml (Life Technologies, Karlsruhe, Germany). Cells were cloned by subsequent selection with colchicine at 40 ng/ml; 24 clones were analyzed.
Maintenance and soft-agar colony assays for K562 cells as well as sources, enrichment and colony assays for primary CD34 + cells were as described. [6] [7] [8] 20, 25 Briefly, umbilical cord blood-derived CD34 + cells were stimulated and transduced under serum-free conditions in medium X-vivo 10 (Boehringer Ingelheim, Heidelberg, Germany) supplemented with a cytokine cocktail consisting of IL3, IL6, SCF, FL (Stem Cell Technologies, St Katharinen, Germany) and anti-TGFb1 antibodies (R&D Systems, Minneapolis, USA). After 20 h prestimulation, transduction was performed over 3 consecutive days using serum-free retroviral supernatant in the presence of protamine sulfate at 4 mg/ml. Cells exposed to supernatants were centrifuged at 1500 g for 90 min on plates coated with the fibronectin fragment CH-296 (Boehringer Ingelheim). One day after the last transduction, cells were harvested, washed and analyzed and sorted using flow cytometry. Retroviral supernatant titration on fibroblast target cells followed established protocols. [6] [7] [8] Flow cytometry Flow cytometry was performed on a FACScalibur (Becton Dickinson) with CellQuest (Becton Dickinson) software. Expression of MDR1 on transduced hematopoietic cells was deteced by flow cytometry using the monoclonal, R-Phycoerythrin-conjugated UIC2-antibody (Coulter Immunotech, Hamburg, Germany). Expression of DLNGFR was analyzed using a biotinylated monoclonal antibody (kindly provided by B Koch, Boehringer, Mannheim, Germany), with Streptavidin-CyChrome (PharMingen, San Diego, CA, USA) as a second-step reagent. Cell sorting was performed with a Becton Dickinson instrument (FACS vantage, Enterprise coherent II) equipped with a 488 nm argon laser. Sorting decisions for DLNGFR-positive cells were adjusted according to the isotype-control. For cell-sorting, DLNGFR was labeled with anti-NGFR antibody (Boehringer Mannheim) and goat anti-mouse F(ab)-FITC as secondary antibodies (Dianova, Hamburg, Germany).
Confocal laser microscopy K562 cells transduced with SF1mSd and selected for multidrug-resistance were stained as described above, but using FITC-conjugated streptavidin (Pharmingen, Hamburg, Germany) for detection of DLNGFR. Cells were fixed with 2% formaldehyde in phosphate-buffered saline and analyzed using a Leica confocal laser scanning microscope (Leica, Bensheim, Germany) equipped with an argon/krypton laser and a 63×, 1.4 N.A. objective.
